Money Talks: The Market Forces Behind TAVR’s Coverage Overhaul

The clinical questions surrounding TAVR — heart teams, evidence development, patient selection, and long-term outcomes — appropriately receive substantial attention. But the policy conversation also has an important market dimension. As Medicare coverage has evolved, so has the size and complexity of the structural heart market. Understanding those incentives does not diminish the clinical case for expanded access; it helps hospitals and service-line leaders evaluate the proposal with a clear view of both opportunity and responsibility.

A Policy Reconsideration Shaped by New Evidence and Market Momentum

The 2026 reconsideration did not emerge in a vacuum. CMS initiated the review after a formal request from Edwards Lifesciences, following FDA activity and new clinical evidence related to TAVR in asymptomatic severe aortic stenosis. That sequence is not unusual in medtech policy: manufacturers often generate pivotal evidence, seek regulatory expansion, and then pursue coverage alignment. For providers, the key point is not to assign motive, but to recognize that evidence generation, regulatory strategy, and market expansion are closely connected in structural heart care.

The Math of Expansion

From a market-planning perspective, the proposal points toward growth. Covering select asymptomatic patients could expand the eligible population. Broader use in younger or lower-risk patients may also increase the importance of lifetime valve management, including surveillance, reintervention planning, and coordination across the cardiovascular service line. If site and operator requirements become more flexible and CED requirements are reduced for symptomatic patients, more programs may consider whether TAVR fits their local access strategy. The result is not simply “more procedures,” but a broader restructuring of how hospitals plan, staff, measure, and differentiate structural heart programs.

A Pattern, Not a One-off

The pattern across TAVR coverage policy is one of progressive modernization as evidence, technology, operator experience, and patient demand have matured. The 2019 update reflected growing real-world experience and expansion into intermediate-risk populations. The 2026 proposal continues that trajectory, while raising a different set of questions: How should access expand without weakening quality oversight? How should programs demonstrate outcomes if registry participation is no longer tied to coverage for some patients? And how should hospitals balance market opportunity with the clinical infrastructure needed to support durable, patient-centered care?

What the Money Can’t Settle

None of this makes expansion inappropriate. Earlier treatment may benefit certain patients, and industry-sponsored research has played a meaningful role in advancing the field. Still, financial alignment and clinical certainty are not the same thing. As TAVR moves into broader populations, the remaining questions — valve durability, patient selection, lifetime management, and outcomes in lower-risk patients — become increasingly important. If evidence-collection requirements change, hospitals and heart teams may need to take a more deliberate role in maintaining data discipline through registries, quality programs, and internal performance review.

What to Watch

The final decision will signal how CMS balances access, evidence, and program flexibility. For hospital leaders, the more immediate question is strategic: if the market opens further, will the organization compete on volume alone, or on a clearly defined structural heart model built around multidisciplinary evaluation, measurable outcomes, and long-term valve care? That is where the financial implications become most relevant — not as a critique of any one stakeholder, but as a reminder that sustainable growth requires clinical rigor, operational readiness, and transparent quality performance.

Sources

• Cardiovascular Business — industry and advocacy reactions (Edwards, Medtronic, and the Alliance for Aging Research “transformative milestone” statement).
• TCTMD — Edwards’ reconsideration request, EARLY TAVR (TCT 2024; NEJM), and the FDA Sapien 3 asymptomatic approval (May 2025).
• CMS, Proposed Decision Memo for TAVR (CAG-00430R2) — December 2025 reconsideration and June 15, 2026 memo.
• Joint society comment letter — AATS, ACC, HFSA, SCAI, and STS, January 14, 2026.
• MedTech Dive and Healthcare Dive — market context and asymptomatic-disease prevalence.

By Steven D. Harrington, MD, MBA, FACS, ABTS, FACC, FACCP